The nearly simultaneous launch of a plethora of new antiretroviral agents with expanded activity in existing (tipranavir, darunavir, and etravirine) and novel classes (raltegravir and maraviroc) has resulted in unprecedented success for human immunodeficiency virus type 1 (HIV-1)-infected patients who have received multiple treatments. Currently achieved virological suppression rates in patients with triple-class failure were until recently only seen in drug-naive patients [1, 2] . It is critical that clinicians use the available agents carefully and become familiar with the complexity of dealing with their resistance patterns.
The nearly simultaneous launch of a plethora of new antiretroviral agents with expanded activity in existing (tipranavir, darunavir, and etravirine) and novel classes (raltegravir and maraviroc) has resulted in unprecedented success for human immunodeficiency virus type 1 (HIV-1)-infected patients who have received multiple treatments. Currently achieved virological suppression rates in patients with triple-class failure were until recently only seen in drug-naive patients [1, 2] . It is critical that clinicians use the available agents carefully and become familiar with the complexity of dealing with their resistance patterns.
These new drugs have demonstrated superiority in key efficacy parameters in their salvage trials [3] [4] [5] [6] [7] [8] [9] [10] . Unfortunately, we lack comparative trials between them. Trials generally have evaluated only a single new drug, the exception being darunavir and etravirine in the DUET trials. Preliminary reports of combined use of these new drugs in routine clinical practice show very promising results [11] .
Table 1. Important Steps to Be Checked for Successfully Designing Salvage Therapy Regimens
Step no Description 1 Determine the cause of the current regimen failure. Take measures to resolve it and avoid its recurrence in the subsequent new regimen. 2 Review all previous resistance test results available as well as the current one. Compile all results and interpret. Prior documented mutations remain in small undetectable subpopulations but will emerge when suboptimal drug pressure is exerted again, even if undetected by the present tests.
3
Thoroughly review the full treatment history, and specifically identify all drugs included in failing regimens, and those associated with intolerance. Suspect the presence of mutations against drugs (lamivudine, emtricitabine, nevirapine, efavirenz, enfuvirtide, raltegravir) included in regimens which have previously failed, despite the fact that mutations were not detected in genotypes. 4 Review potential drug-drug interactions and consider therapeutic drug monitoring if available and indicated.
5
Focus on maximizing patient's adherence to treatment. Poorly adherent patients are overrepresented among those with virological failure. 6 Strive to include 3 fully active drugs or their equivalent in the new treatment regimen in all patients with prior triple-class failure and resistance.
7
Consider obtaining a tropism test in all patients, even if a CCR5 antagonist use is not planned initially. 8 Patients with high viral loads and lower CD4 cell counts have consistently lower response rates. Take special care with this subset of patients to optimize salvage regimens including three fully active agents.
9
In complex cases with multidrug resistance, obtain the opinion and the support of an expert in human immunodeficiency virus resistance. feasible strategy when local availability of experts is lacking, providing expert advice along with continued education [19] . Some guidelines still recommend a viral load 1500-1000 copies/mL for genotypic testing. However, rates of amplification 170% can usually be obtained with viral loads 1100 copies/mL [14, 20] .
Tropism testing must be routinely assessed. An R5-only tropism result will allow use of maraviroc either in the initially planned regimen or as an alternative if toxicity to another drug is encountered. Tropism testing is not standardized once viral load becomes undetectable [21, 22] .
The inclusion of enfuvirtide in treatment has been associated with significant increases in response rates in all salvage trials. Although its use is currently vestigial because of treatment inconvenience and widespread substitution with alternative oral drugs (mainly raltegravir), its contribution to regimen activity should not be forgotten when options are limited [3] [4] [5] [6] [7] [8] [9] [10] [23] [24] [25] [26] [27] .
The success of salvage therapy lies in closely adhering to a series of basic principles (Table 1) . It is crucial to design an optimal regimen which allows for effective and durable viral suppression while minimizing toxicity, inconvenience, and cost.
The scores, or lists, of mutations that confer resistance include mutations selected in vitro by passage experiments, those that result in drug resistance and decreased response in vivo, and those that appear in patients who experience virological failure.
TIPRANAVIR
Tipranavir is a nonpeptide protease inhibitor with activity against strains with multiple protease mutations, approved for use in treatment-experienced patients. A full resistance score was initially derived, with the following 21 mutations: 10V, 13V, 20M/R/V, 33F, 35G, 36I, 43T, 46L, 47V, 54A/M/V, 58E, 69K, 74P, 82L/T, 83D, and 84V [3, 28] . A weighted score then assigned 5 mutations (24I, 50V/L, 54L, and 76V) a negative score (eg, increased response to treatment) [29, 30] . The score has recently been updated (Table 2) , achieving a better prediction of response [31, 33] . The most commonly selected mutations in patients with virological failure are A82T, I84V, and I24L/M [32] .
Phenotypic clinical cut-offs associated with a 20% (clinical cut-off 1) and 80% (clinical cut-off 2) loss of response have Figure 1 . Numbers of virological failures (VFs) (A) and development of resistance (B, C) in the patients with VF observed in the TITAN study [41] . DRV/r, darunavir/ritonavir; LPV/r, lopinavir/ritonavir; PI, protease inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; OBR, optimized background regimen; RAM, resistance-associated mutation. *Baseline and end point genotype available for 28 of 31 VFs; †Baseline and end point genotype available for 56 of 65 VFs; **Baseline and end point phenotypes available for 28 of 31 VFs (2 of 28 had decreased susceptibility to DRV at baseline); ‡Baseline and end point phenotype available for 54 of 65 VFs (12 of 54 had decreased susceptibility to LPV at baseline).
been established at 1.2-2 and 5.4-8 [34] . A phenotypic fold change !0.5 has been associated with more durable response [35] .
The use of tipranavir is limited to those cases who meet 2 criteria: (1) its predicted activity significantly surpasses that of darunavir, and (2) etravirine use is not planned. There is a clinically relevant pharmacokinetic interaction that reduces etravirine exposure, precluding their coadministration [36] . Of importance, I50V, I54L, and L76V confer resistance to darunavir but hypersusceptibility to tipranavir, which can have a discriminatory role in their selection, particularly following treatment failures with amprenavir, lopinavir, or darunavir.
DARUNAVIR
Darunavir has been approved in treatment-naive patients and in initial and advanced salvage regimens, where it is the standard-of-care protease inhibitor [4, 10, 37] . Activity is preserved among non-B HIV-1 subtypes [38, 39] .
In naive patients, it is administered once-daily at doses of darunavir/ritonavir 800/100 mg. In all other situations, the approved dose is 600/100 mg twice daily. However, there are prospects regarding the use of the once-daily dose in selected pretreated patients without significant darunavir resistance, with ongoing trial results eagerly awaited [40] . This is based on the high inhibitory quotient achieved, its long plasma halflife (∼15 h), and preliminary findings of phase II studies. Similar to other boosted protease inhibitors, neither primary mutations nor phenotypic resistance to darunavir are selected naive patients who experience virological failure [38] .
In lopinavir-naive, treatment-experienced patients (TITAN study), darunavir was superior to lopinavir [10] . It was also superior provided there was at least 1 baseline primary protease mutation (IAS-USA list), 3 lopinavir resistance mutations, or the lopinavir fold change was 110.
New mutations in cases of treatment failure and loss of susceptibility to the protease inhibitor were lower with darunavir ( Figure 1 ) [41] . Thus, darunavir protects the background regimen activity better than lopinavir in patients who experience early failure. In patients with advanced HIV-1 infection, darunavir also demonstrated superiority to the comparator protease inhibitor [4] .
The current score of mutations conferring resistance include V11I, V32I, L33F, I47V, I50V, I54L/M, T74P, L76V, I84V, and L89V [4, 10, 42] . They have been associated with a reduction in the in vitro sensitivity and clinical response and appeared in at least 10% of patients with virological failure (V32I, L33F, I47V, I54L, and L89V appeared most frequently).
An optimal response to darunavir was associated with a phenotypic fold change р10 (upper clinical cut-off defined at 90) [41] . A linear loss of response begins to occur with the first mutation, and beyond 3 mutations, the response is greatly reduced ( Figure 2) . Nonetheless, complete resistance to darunavir is rare, and its exclusion in a salvage regimen must be carefully assessed [44] .
N88S is associated with a reduction in the phenotypic fold change. Statistically, the presence of V82A has been associated with a lower fold change, a higher rate of response, and a greater viral load decrease [45] . These data are relevant, because V82A is one of the most common protease mutations seen in clinical practice [46] .
There is a significant overlap between the molecular structures and mutational resistance patterns of darunavir and am- Analysis was done by TLOVR among those with human immunodeficency virus (HIV) RNA levels !50 copies/mL at 24 weeks (non-virological failures were censored) and was performed in the POWER 1, 2 (darunavir arms), and 3 and DUET 1 and 2 studies. *In those cases in which there was a mixture of mutations in a certain position, only one mutation was counted per position; # The reference response rate of the comparator arm without darunavir in studies POWER 1 and 2 was 12%. Note that patients had a median of 13 IAS-USA protease mutations (DRM). The 2007 set of mutations for darunavir included V11I, V32I, L33F, I47V, I50V, I54L/M, G73S, L76V, I84V, and L89V. G73S currently substituted by T74P [43] . PI, protease inhibitor; RAM, resistance-associated mutation. Derived from De Meyer et al [42] .
prenavir. Although darunavir's inhibitory quotient is far higher, in patients with fosamprenavir failure, the efficacy of darunavir could be reduced, particularly when I50V or V32I plus I47V are present [47] .
Fortunately, darunavir and tipranavir mutation patterns are somewhat different, each of them being a potential candidate in the event of failure of the other [48] . I50V, I54L, and L76V confer significant resistance to darunavir but hypersusceptibility to tipranavir and, therefore, may be of substantial importance in this scenario. L33F, I54M, I47V, T74P, and I84V confer resistance to both drugs. I84V favored darunavir in a multivariate analysis, whereas I47V favored tipranavir [49] .
Virtually all pivotal salvage trials have included a protease inhibitor [3, 6, 7, 9, 23] . However, in unusual situations (patient intolerance and established resistance) physicians may be forced to use protease inhibitor-sparing regimens. Because of the availability of etravirine, maraviroc, raltegravir, and enfuvirtide, these regimens may actually include 3 fully active drugs even in heavily pretreated individuals. Preliminary reports have described very high rates of virological suppression when the sensitivity score of the regimen was similar to that of patients receiving a protease inhibitor [50] . The number of active antiretrovirals, but not the inclusion of a protease inhibitor, was a predictor of response, suggesting that the crucial point for success lies in the inclusion of multiple fully active drugs.
ETRAVIRINE
Etravirine has activity against HIV-1 strains resistant to first-generation nonnucleoside reverse-transcriptase inhibitors (NNRTIs) [51] . Approved for patients with previous treatment failures, it retains full activity against K103N mutants, the most common mutation seen with resistance to first-generation NNRTIs [52] .
Etravirine activity varies according to the number and type of NNRTI mutations selected. It has a higher genetic barrier than older NNRTIs, requiring multiple mutations for loss of activity [16, 53] .
Its clinical efficacy and safety have been demonstrated in the TMC125-C223 and DUET studies [5, 6, 54, 55] , which included patients pretreated with nucleoside reverse-transcriptase inhibitors (NRTIs), NNRTIs, and protease inhibitors. In the DUET studies, all patients also received darunavir/ritonavir, resulting in much higher rates of efficacy.
Conversely, etravirine was inferior to a protease inhibitor in protease inhibitor-naive patients with previous NNRTI failures (TMC125-C227 trial), indicating that a certain degree of crossresistance exists within the class [56] . A post hoc analysis identified the presence of Y181C, a fold change у10, and a higher number of etravirine mutations, with a diminished response. The mutation pattern of etravirine is well characterized, although uncommon mutations may not be represented in some scores [52, 57] .
Essentially, 3 independent genotypic scores have been developed. The first has been correlated with treatment response [57] . Overall, the presence of 3 etravirine mutations was associated with a reduced response, though the weight for each mutation was different. Seventeen mutations have now been identified (Tables 3 and 4 ) [57] . The most common are Y181C and G190A. More recently, E138G/Q substitutions have also been associated with etravirine resistance [58] . Intermediate etravirine activity is commonly observed in patients who have accumulated mutations after first-generation NNRTI failures [52] . This must be considered when designing the regimen to obtain an optimal response. Nevertheless, complete etravirine resistance is uncommon [52] . In the DUET studies, etravirine protected the activity of darunavir, reducing the proportion of patients developing darunavir mutations (Figure 3) [61] .
A second score based on the correlation with 4248 phenotypes identified 30 mutations (Tables 3 and 4 ) [62] . Although the mutations included and the scores given differ slightly, the final interpretation of both scores and the Stanford Database one is very similar (Tables 3 and 4) [59, 60] . The last score does not grant points to polymorphic mutations (V90I and V106I) but grants 10 points to K103N (a marker of previous NNRTI exposure and risk of coexistence of further mutations). Phenotypic lower and higher clinical cut-offs have been set at 1.6-3 and 13-27.6, respectively, depending on the test manufacturer [34, 63, 64] .
Some NRTI mutations (M41L, D67N, T69D/N, K70R, L74I/ V, M184V, L210W, T215F/Y, and K219N/Q/R) confer etravirine hypersusceptibility, an issue not yet assessed in any score. In the DUET studies, 34% of all samples displayed a fold change !0.4 [65] . The clinical significance of this not defined yet.
Efavirenz failures select for K103N, L100I, Y188L, G190A, and K101E in subtype B virus, whereas nevirapine selects Y181C, K103N, G190A, K101E, and A98G [66] . Whether one or the other are associated with higher rates of etravirine failure is still uncertain [67, 68] . Although nevirapine selects for mutations with higher impact on etravirine (particularly Y181C), the rate of selection of mutations was higher for efavirenz [69] . In the analysis with the higher degree of evidence (599 etravirine-treated patients), the rate of response was virtually the same with both, and a prior nevirapine failure was not a predictor of response [70] .
RALTEGRAVIR
Raltegravir is the first approved HIV-1 integrase strand-transfer inhibitor for both naive and treatment-experienced patients, with elvitegravir in late clinical development. The HIV-1 integrase catalyses the insertion of viral complementary DNA into host DNA and was not routinely sequenced in genotypes [7, 71, 72] .
The drug is active against wild-type HIV-1; viruses with resistance against NRTIs, NNRTIs, and protease inhibitors (no cross-resistance with other classes); and viruses with CCR5 or CXCR4 tropism. It suppresses plasma HIV-1 RNA levels significantly faster than other current drugs, though the clinical relevance of this is unknown [73, 74] .
Raltegravir does not demonstrate the high genetic barrier to resistance seen with a boosted protease inhibitor. Thus, it is Susceptible, correlates to a fold change !2.9 у4
Intermediate resistance, correlates with a fold change 12.9 Emerging darunavir mutations in patients with virological failure in the DUET study. The most frequently emerging darunavir mutations in both arms were V32I and I54L [10, 61] . BR, background regimen; ETR, etravirine.
critical to secure its protection with other active agents. On treatment failure, resistance mutations are seen to accumulate, and considerable reductions in susceptibility are seen with single key mutations. Phenotypic clinical cut-offs have not yet been determined. Genotypic resistance commonly emerges in patients with virological failure, with substantial cross-resistance to elvitegravir (Figure 4) [76] . A higher baseline viral load and a background regimen without active agents were associated with the development of mutations, the most common being N155H (incidence, ∼40%) and Q148H/R/K (incidence, 28%-30%), representing 2 mostly exclusive pathways. Other less common resistance pathways are Y143R/C (7%), E157Q, and E92Q.
Q148 substitutions are associated with increases in resistance of up to 25-fold, compared with an average of 10-fold with N155H. Isolated N155H mutations might potentially be overcome by other integrase inhibitors-opening the door to possible sequential use of newer agents of the class. In patients experiencing treatment failure, accessory mutations accumulate, which either increase the degree of resistance or restore viral fitness (eg, G140S rescues the integration defect induced by Q148H) [77] .
In patients experiencing early failure, N155H predominates because selective advantage, but under continued treatment, there is often a gradual replacement by Q148H/R/K [78] . The degree of resistance increases if virological failure persists. The rate at which resistance increases varies substantially between patients, and high-level resistance could sometimes require months of persistent replication [77] . Early withdrawal of raltegravir would help in preventing high levels of integrase resistance. Integrase resistance testing or storing of samples from patients with treatment failure of integrase inhibitor-based regimens should always be considered.
MARAVIROC
Maraviroc is currently the only approved CCR5 coreceptor antagonist, with vicriviroc in advanced clinical development, representing the first antiretroviral class that does not target the virus. Rather, it acts as a noncompetitive inhibitor on a human cell coreceptor required for viral entry. CCR5 and CXCR4 are cell surface receptors for various natural ligands [21] . It binds only to the CCR5 receptor and, therefore, has no activity against X4-tropic viruses [79] . It has been approved in both treatmentnaive and treatment-experienced patients [8, 9, 80, 81] . Approximately 85% of treatment-naive and 50% of treatmentexperienced individuals harbor R5-only tropic viruses [82] .
Intrinsic resistance to maraviroc with CCR5 tropism appears to be rare. There is no cross-resistance with enfuvirtide, which selects for resistance in the gp41 envelope region [21] .
Prior to its use, the presence of CCR5 tropism needs to be confirmed. Currently, the only validated test is the Trofile phe- Figure 4 . Substitutions in the integrase associated with resistance to the integrase inhibitors. RAL, raltegravir; EVG; elvitegravir. Previously published in [75] . Used with permission of the publisher.
notypic assay (Monogram). The original assay (no longer available) has been replaced by a more sensitive version (ES Trofile), which detects strains with R5/X4 dual/mixed tropism or X4 tropism present in 0.1%-0.3% of the viral population. However, this technology is propriety and is performed only in California, requires worldwide sample shipment, and is expensive, with a long turnaround time.
A variety of genotyping techniques to predict tropism have been tested [83] . Envelope V3 loop sequence is determined and interpreted using a public domain software (http://www .geno2pheno.org/) [84] . The gp41 transmembrane subunit and other sequences of the envelope external to V3 may also be determining factors in tropism switches [85, 86] . The overall correlation has shown a sensitivity of 60%, with 90% specificity, of population-based V3 genotyping algorithms, compared with the original Trofile assay [87] . However, their clinical utility was much the same, with all of them similarly discriminating short-term responders. Genotypic assays are less expensive, have faster turnaround times, and can be performed in local labs. Furthermore, massive parallel pyrosequencing with 454 technologies will allow more sensitive genotypic detection of CXCR4-tropic variants [88] .
Clinical resistance to CCR5 antagonists emerges through 2 different mechanisms. The first one consists of a change to the use of CXCR4 coreceptor. This occurred in 57% of patients experiencing failure with maraviroc; it is apparently not selected de novo during treatment failure but is attributable to preexisting minority X4 populations [8, 88] . The development of the more sensitive ES Trofile assay may reduce the number of treatment failures that occur through X4-tropic virus emergence [81] .
The second mechanism involves true viral resistance through mutations in gp120. This results in a plateau effect in the doseresponse curves [89] ; ie, increasing concentrations do not increase the percentage of viral inhibition because HIV-1-resistant clones are able to bind to the receptor occupied by maraviroc (allosteric inhibition).
The base of the V3 loop remains generally intact, with mutations concentrating in the stem of the loop. The residues 316 and 323 seem to play a key role, and mutations commonly described in V3 are I20F, A25D, and I26V. However, much remains to be discovered, and the pattern of mutations seems to be very heterogeneous, with changes outside V3 having a contribution as well. High rates of viral suppression are seen when maraviroc is combined with the equivalent of 2 active drugs, with genotypic and phenotypic weighted susceptibility scores equally predicting response [90, 91] .
X4 usage increases spontaneously with duration of HIV-1 infection. Therefore the potential benefit of CCR5 antagonists is greatest early in infection, suggesting that efforts to encourage usage in this scenario should be further pursued.
CONCLUSIONS
The entrance of potent new antiretroviral agents into the clinical realm has revolutionized the care of treatment-experienced patients. Proper use of these new drugs and drug classes requires a basic understanding of their resistance characteristics. Pivotal studies indicate that salvage regimens in patients with prior triple-class failure and resistance optimally should include 3 active agents or their equivalent. However, active drugs in these studies were often enfuvirtide, the study drug, and recycled NRTIs. Combinations of multiple new antiretroviral drugs have not yet been evaluated in randomized studies, but preliminary data suggest outstanding results when used in combination [11, 70] . The inclusion of at least 1 drug of a new class is strongly recommended. Failure of these drugs can quickly lead to loss of activity and even class cross-resistance, leaving patients with few if any options for the near future. The need for continued use of inactive NRTIs and non-protease inhibitor containing regimens remain to be determined. mens, Ambrillia, and BMS; B.C. has received research funding, consultancy fees, or lecture sponsorships from, or has served on advisory boards for Abbott, Boehringer-Ingelheim, Gilead Sciences, GlaxoSmithKline, JanssenCilag, Merck Sharp & Dohme, Panacos, Pfizer, Roche, and Tibotec.
